Now a Stand-alone Firm, AB Sciex to Invest Further into R&D, Explore Acquisition Opportunities

With its sale to Danaher closed, AB Sciex will invest further into development of its mass specs and explore acquiring new technologies to strengthen its technology portfolio, company officials said on Tuesday.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.